Prostate-specific membrane antigen (PSMA) PET/CT has been validated as a method to determine the benignity/malignancy of localized renal tumors and the WHO/ISUP grade of ccRCC (13, 14). This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.